OBJECTIVE: To examine whether use of adjuvant therapy varies by race/ethnicity among patients with ductal carcinoma in situ (DCIS) at 3 integrated health plan delivery sites based in California and Massachusetts. STUDY DESIGN: Cross-sectional study nested within a cohort of women diagnosed as having DCIS between 1990 and 2001. METHODS: We reviewed medical records of 3000 non-Hispanic white (69%), black (10%), Hispanic (9%), and Asian or Pacific Islander (12%) women diagnosed as having DCIS between 1990 and 2001 and treated with breast-conserving therapy. chi(2) Test and multinomial logistic regression analysis were used to examine the association between race/ethnicity and use of adjuvant treatments after controlling for patient and clinical variables, including certain pathologic factors. RESULTS: We found no significant differences in DCIS adjuvant treatment among racial/ethnic groups in bivariate or multinomial analyses after adjusting for demographic characteristics, comorbidity, and clinical factors. Minority women were as likely to undergo adjuvant radiation therapy as non-Hispanic white women. However, women 70 years or older (odds ratio, 0.40; 95% confidence interval, 0.31-0.51) and women who lived in areas with low geocoded median family income (odds ratio, 0.65; 95% confidence interval, 0.48-0.89) were less likely to receive adjuvant radiation therapy. Tumor size and comedo histologic growth pattern were associated with increased likelihood of receiving radiation therapy. CONCLUSION: Use of adjuvant therapy by minority women in these managed care plans is similar to that by non-Hispanic white women, although use was less among older women and among women who lived in poorer neighborhoods.
OBJECTIVE: To examine whether use of adjuvant therapy varies by race/ethnicity among patients with ductal carcinoma in situ (DCIS) at 3 integrated health plan delivery sites based in California and Massachusetts. STUDY DESIGN: Cross-sectional study nested within a cohort of women diagnosed as having DCIS between 1990 and 2001. METHODS: We reviewed medical records of 3000 non-Hispanic white (69%), black (10%), Hispanic (9%), and Asian or Pacific Islander (12%) women diagnosed as having DCIS between 1990 and 2001 and treated with breast-conserving therapy. chi(2) Test and multinomial logistic regression analysis were used to examine the association between race/ethnicity and use of adjuvant treatments after controlling for patient and clinical variables, including certain pathologic factors. RESULTS: We found no significant differences in DCIS adjuvant treatment among racial/ethnic groups in bivariate or multinomial analyses after adjusting for demographic characteristics, comorbidity, and clinical factors. Minority women were as likely to undergo adjuvant radiation therapy as non-Hispanic white women. However, women 70 years or older (odds ratio, 0.40; 95% confidence interval, 0.31-0.51) and women who lived in areas with low geocoded median family income (odds ratio, 0.65; 95% confidence interval, 0.48-0.89) were less likely to receive adjuvant radiation therapy. Tumor size and comedo histologic growth pattern were associated with increased likelihood of receiving radiation therapy. CONCLUSION: Use of adjuvant therapy by minority women in these managed care plans is similar to that by non-Hispanic white women, although use was less among older women and among women who lived in poorer neighborhoods.
Authors: Joann G Elmore; Connie Y Nakano; Hannah M Linden; Lisa M Reisch; John Z Ayanian; Eric B Larson Journal: Med Care Date: 2005-02 Impact factor: 2.983
Authors: Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: Chelsea Anderson; Anne Marie Meyer; Stephanie B Wheeler; Lei Zhou; Katherine E Reeder-Hayes; Hazel B Nichols Journal: Oncologist Date: 2017-04-13
Authors: Debra P Ritzwoller; Nikki Carroll; Thomas Delate; Maureen O'Keeffe-Rossetti; Paul A Fishman; Elizabeth T Loggers; Erin J Aiello Bowles; Jennifer Elston-Lafata; Mark C Hornbrook Journal: Med Care Date: 2013-10 Impact factor: 2.983
Authors: Laura C Collins; Ninah Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Charles P Quesenberry; Stuart J Schnitt; Laurel A Habel Journal: Breast Cancer Res Treat Date: 2013-04-27 Impact factor: 4.872
Authors: Chinwe C Madubata; Ying Liu; Melody S Goodman; Shumei Yun; Jennifer Yu; Min Lian; Graham A Colditz Journal: Breast Cancer Res Treat Date: 2016-10-22 Impact factor: 4.872
Authors: Meghan R Flanagan; Mara H Rendi; Vijayakrishna K Gadi; Kristine E Calhoun; Kenneth W Gow; Sara H Javid Journal: Ann Surg Oncol Date: 2015-07-23 Impact factor: 5.344
Authors: Hazel B Nichols; Erin J A Bowles; Jessica Islam; Lawrence Madziwa; Til Stürmer; Diem-Thy Tran; Diana S M Buist Journal: Oncologist Date: 2016-01-14